KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+61.8%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+61.8%/yr
Quarterly compound
Percentile
P85
Within normal range
vs 3Y Ago
4.2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 40.04% |
| Q3 2025 | -35.03% |
| Q2 2025 | -23.51% |
| Q1 2025 | 17.56% |
| Q4 2024 | 1.44% |
| Q3 2024 | -166.27% |
| Q2 2024 | 45.21% |
| Q1 2024 | -39.07% |
| Q4 2023 | 25.83% |
| Q3 2023 | -18.09% |
| Q2 2023 | -143.69% |
| Q1 2023 | 54.89% |
| Q4 2022 | 9.45% |
| Q3 2022 | 15.11% |
| Q2 2022 | -90.47% |
| Q1 2022 | 28.04% |
| Q4 2021 | -10.21% |
| Q3 2021 | -60.57% |
| Q2 2021 | -45.60% |
| Q1 2021 | 4.60% |
| Q4 2020 | -121.63% |
| Q3 2020 | 71.56% |
| Q2 2020 | 3.75% |
| Q1 2020 | -67.76% |
| Q4 2019 | 30.70% |
| Q3 2019 | -7.27% |
| Q2 2019 | 3.18% |
| Q1 2019 | -23.56% |
| Q4 2018 | -41.44% |
| Q3 2018 | -4.32% |
| Q2 2018 | -121.10% |
| Q1 2018 | 488.76% |
| Q4 2017 | -63.20% |
| Q3 2017 | -68.42% |
| Q2 2017 | -23394.35% |
| Q1 2017 | 99.30% |
| Q3 2016 | 77.74% |
| Q2 2016 | -42.80% |
| Q1 2016 | -0.34% |
| Q4 2015 | 4.50% |